Helmholtz Gemeinschaft


Issues in antiplatelet therapy for UA/NSTEMI

Item Type:Article
Title:Issues in antiplatelet therapy for UA/NSTEMI
Creators Name:Chatterjee, K. and Col, J. and Dalby, A.J. and Gulba, D.
Abstract:Options for antiplatelet therapy have increased in the last decade, with thienopyridines and GP IIb/IIIa receptor antagonists joining aspirin on the roster of available antiplatelet agents. Both North American (ACC/AHA) and European (ESC) cardiology societies have made recommendations regarding the use of antiplatelet agents in recently issued practice guidelines for the management of acute coronary syndromes without ST-segment elevation. In September 2000, a group of international cardiologists meeting under the auspices of the International Cardiology Forum participated in a workshop to examine the new antiplatelet recommendations. Workshop participants generally agreed that both sets of guidelines were satisfactory, however there were areas of disagreement. The most controversial topic was the role of GP IIb/IIIa antagonists. Given the evidence for efficacy of these agents for medical management, many participants felt that their use was overemphasized. There was strong support for the use of GP IIb/IIIa inhibitors in the setting of intervention, although cost is prohibitive in many countries. In view of real-world limitations, guidelines for alternative management strategies are needed.
Keywords:Antiplatelet, GP IIb/IIIa Antagonist, Acute Coronary Syndromes, Unstable Angina, Guidelines
Source:European Heart Journal Supplements
Publisher:Oxford University Press
Number:Suppl J
Page Range:J24-J31
Date:August 2001
Official Publication:https://doi.org/10.1016/S1520-765X(01)90137-3

Repository Staff Only: item control page

Open Access
MDC Library